Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?

被引:0
作者
Peter Steele
Geoff Strange
John Wlodarczyk
Brad Dalton
Simon Stewart
Eli Gabbay
Anne Keogh
机构
[1] Royal Adelaide Hospital,Department of Cardiology
[2] Monash University,Department of Epidemiology and Preventative Medicine
[3] New Lambton,John Wlodarczyk Consulting Service
[4] University of Tasmania,School of Human Life Sciences
[5] Launceston,Western Australian Lung Transplant Unit and Pulmonary Hypertension Service
[6] TAS,Victor Chang Research Institute
[7] and medScript,undefined
[8] Baker Heart Research Institute,undefined
[9] Royal Perth Hospital,undefined
[10] St Vincent's Hospital,undefined
来源
BMC Cardiovascular Disorders | / 10卷
关键词
Pulmonary Arterial Hypertension; Bosentan; Iloprost; Vardenafil; Epoprostenol;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 540 条
[1]  
Rubin LJ(1997)Primary pulmonary hypertension N Engl J Med 336 111-117
[2]  
Barst RJ(1996)A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group N Engl J Med 334 296-302
[3]  
Rubin LJ(1999)Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects Circulation 99 1858-1865
[4]  
Long WA(1991)Survival in patients with primary pulmonary hypertension. Results from a national prospective registry Ann Intern Med 115 343-349
[5]  
McGoon MD(2001)Primary pulmonary hypertension in Israel: a national survey Chest 119 1801-1806
[6]  
Rich S(2004)Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines Chest 126 78S-92S
[7]  
Badesch DB(1994)Survival in primary pulmonary hypertension. Validation of a prognostic equation Circulation 89 1733-1744
[8]  
Groves BM(2008)Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial J Am Coll Cardiol 52 2127-2134
[9]  
Tapson VF(2008)Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension Chest 134 229-236
[10]  
Bourge RC(2004)Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure Am J Cardiol 94 1475-1477